Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

FeRx and Elan to develop MTC-DOX for treatment of liver cancer

Nov. 30, 2000

Deltagen obtains license to develop potential AML treatment

Nov. 30, 2000

Enhanced expression of p21 associated with responses to rAd-p53 gene therapy in NSCLC

Nov. 29, 2000

PK-11195 is able to sensitize cholangiocarcinoma cells to radiation-induced apoptosis

Nov. 29, 2000

Favorable pharmacokinetic and tolerability profile for Angiozyme in humans

Nov. 29, 2000

Antitumor agents from Spanish university induce apoptosis

Nov. 28, 2000

Oncologic Drugs Advisory Committee meeting in mid-December has a full agenda

Nov. 28, 2000

CI-1042 shows biological activity in refractory head and neck cancer

Nov. 28, 2000

Servier compares in vitro/in vivo antitumor activity of new olivacines to doxorubicin and VP-16

Nov. 27, 2000

MGI Pharma and MethylGene begin phase II evaluation of MG-98 in head and neck cancer

Nov. 27, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.